-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Wu2tYj3n5ZefMgXt8RGZ9pKceo0jUYa0r2DPk6lajUKUnTvqyHAVlTNIpN358fef
 zYkCTFhCBSuOzNXYan+4hg==

<SEC-DOCUMENT>0001144204-04-023131.txt : 20041230
<SEC-HEADER>0001144204-04-023131.hdr.sgml : 20041230
<ACCEPTANCE-DATETIME>20041230112129
ACCESSION NUMBER:		0001144204-04-023131
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20041202
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
FILED AS OF DATE:		20041230
DATE AS OF CHANGE:		20041230

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROYCE BIOMEDICAL INC
		CENTRAL INDEX KEY:			0000947011
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980206542
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29895
		FILM NUMBER:		041232835

	BUSINESS ADDRESS:	
		STREET 1:		1100-1200 W 73RD AVENUE
		CITY:			VANCOUVER BC V6X 2B3
		STATE:			A1
		ZIP:			0000

	MAIL ADDRESS:	
		STREET 1:		1100-1200 W 73RD AVENUE
		CITY:			VANCOUVER
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v10566_8k.txt
<TEXT>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT


     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                                December 2, 2004
                        ---------------------------------
                        (Date of earliest event reported)


                             ROYCE BIOMEDICAL, INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)


             Nevada                   000-29895                98-0206542
- ------------------------------       -----------          -------------------
(State or other jurisdiction of      Commission            (I.R.S. Employer
incorporation or organization)       File Number          Identification No.)


                            433 Town Center Suite 316
                             Corte Madera, CA 94925
               --------------------------------------------------
               (Address of principal offices, including Zip Code)


                                 (646) 536-7617
              ----------------------------------------------------
              (Registrant's telephone number, including area code)

<PAGE>

Section 5 - Corporate Governance and Management

Item 5.02. Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.

Effective as of December 2, 2004, Helen Zhao and Kathy Jiang resigned as members
of the Board and Kathy Jiang resigned as President, Chief Executive Officer and
Chief Financial Officer of Royce Biomedical, Inc., a Nevada corporation
("Royce").

Mr. Yan Xiao Wen, the remaining member of the Board of Directors of Royce,
appointed three new directors to the Board. These new members will serve as
board members until the earlier of their resignation, dismissal or the election
by the shareholders of Royce at an annual shareholder meeting for a new term.
The new appointees are Donald Gee, Joseph C Sienkiewicz and Robert Vivacqua.
After the appointment of the three new directors, Mr. Gee was appointed as
Chairman of the Board of Directors and President and Chief Executive Officer of
Royce and Mr. Sienkiewicz was appointed as Chief Financial Officer and Secretary
of Royce.

Business Experience

The following is a brief account of the education and business experience of
each director and executive officer during the past five years, and any other
directorships held in reporting companies. There are no family relationships
among the persons described below.


Donald Gee
- ----------

Donald Gee, 54, has worked as Chief Financial Officer for a Toronto Stock
Exchange listed gaming company and financial advisor to a national aerospace
company. He is President of Cantech Capital Corp. for over 10 years. Cantech
Capital Corp. provides financial and management consulting services to both
private and publicly listed companies, primarily in Canada, and has over 25
years experience as a Chartered Accountant. He was the principal founder of Gee
& Company Chartered Accountants, a successful Vancouver public accounting firm.
Mr. Gee has served on the boards of several public companies and his chief
strengths include the ability to identify, develop and implement successful
corporate strategies. He is a member of the Chartered Accountants of BC and a
member of the Canadian Institute of Mining and Metallurgy. Mr. Gee currently
serves a President of Acero-martin Exploration Inc.(a TSX Venture listed public
company), Yankee Hat Industries Corp. (a TSX Venture listed public company) and
Madalena Ventures Inc. (a private company).

<PAGE>

Joseph C. Sienkiewicz
- ---------------------

Joseph C. Sienkiewicz, 48, has worked as Chief Financial Officer for Capital
West Funding Partners Inc. since 1999. Mr. Sienkiewicz, a certified public
accountant, has over twenty-five years international business experience
including acquisitions, mergers, capital raising and corporate development.

Mr. Sienkiewicz has held executive management positions in several public and
private corporations subsequent to his career with KPMG, and holds a Masters
Degree in Federal Taxation. Mr. Sienkiewicz has extensive experience in the
public sector in both small cap and Fortune 500 companies and has been involved
with publicly held enterprises for over 25 years.

Robert Vivacqua
- ---------------

Robert Vivacqua, 40, has been engaged for the past seven years as a consultant
for Manulife Financial in addition to his position as a partner in a small
independent Venture Capital firm, RJ Sterling Venture Capital, providing
consulting services for individual investors in the areas of financial/estate
planning, and mortgage facilitation as well as assisting and providing a wide
range of services to small and mid size corporations. Mr. Vivacqua has also
worked within several large and medium sized firms within the investment
industry including Bank of America and Elliott & Page Mutual Funds, which
eventually amalgamated into Manulife Financial. Additionally. Mr. Vivacqua has
facilitated financing transactions for small to mid-sized private and public
companies through his extensive contacts within the investment industry and RJ
Sterling Venture Capital There is no transaction during the last two years, or
any proposed transactions, to which Royce was or is a party with any of Messrs.
Gee, Vivacqua or Sienkiewicz or any member of their respective immediate family

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, as amended, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.

Royce Biomedical, Inc.

By: /s/ Joseph C. Sienkiewicz
    ------------------------------
    Joseph C. Sienkiewicz, Secretary

Date:  December 29, 2004

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
